A Contract Research Organization Supporting Enhanced Clinical Research in Early Drug Development

Xceleron is an established contract research organization that accelerates early drug development through the ability to apply novel clinical designs and safely evaluate drug effects in humans.

Our world-leading, ultra-sensitive AMS technology has enabled clinical research teams worldwide to drastically reduce their development costs and timelines compared to traditional methods.

We provide critical human disposition, bioavailability and metabolism data, including absorption, distribution, metabolism, excretion (ADME) and pharmacokinetic (PK) data for exploratory clinical studies and to support regulatory submission. Our novel approaches can help our clients in clinical research overcome clinical development hurdles and de-risk later stages of drug development.

Xceleron’s expertise and clinical research services have supported over 100 pharmaceutical and biotechnology companies from Phase 0 to Phase III. To date, 7 marketed drugs have used our AMS data for registration. Xceleron has the most experienced team in the application of AMS to clinical programs, with:

  • Unmatched global analytical capacity
  • Dedicated quality assurance professionals
  • Rigorous bioanalytical method development and validation
>> Contact us if you need a clinical research organization to accelerate your drug program
>> See how our services have accelerated drug development programs worldwide
phase0 Xceleron
Obtain preliminary human PK/drug targeting data on candidates before Phase 1		 preclinical Xceleron
Especially useful for biologic candidates, Xceleron can determine the distribution of proteins, anti-bodies and SiRNA in a preclinical study		 phase1 Xceleron
Determine human metabolism in Phase I, obtain intravenous PK with no extra pre-clinical tox and conduct your regulatory mass balance study		 phase2 Xceleron
Ultra-sensitive analytical techniques enable clinical analysis of high potency drugs in sensitive populations